Leap-In Transposase

Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform

Wheeler Bio

The PHASE Platform

How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success

Wheeler Bio

Portable CMC

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

Wheeler Bio

CMC

Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler Bio's Portable CMC® Platform

Wheeler Bio

Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC

Wheeler Bio

Wheeler Bio Announces Grand Opening of Biomanufacturing Facility

Wheeler Bio

Business Leadership

Wheeler Bio Appoints Marc Helouin as Chief Quality and Regulatory Officer

Wheeler Bio

CMC

The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies

Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.

Wheeler Bio

Leadership

Wheeler Bio Appoints Dr. Stewart McNaull as Chief Business Officer

Wheeler Bio

Series A Funding

Wheeler Bio Announces Initial Closing of Series A Round Supporting New Biologics Drug Substance GMP Expansion In Oklahoma

Wheeler Bio

Cell Line Development

Integrating Cell Line and CMC Development

Stephen Hamilton, Ph.D.; Mike Brem

Wheeler Bio

Financing

Wheeler Bio Announces $14M Seed Round To Expand Access To Portable CMC™

Wheeler Bio